TS-075259 — More than a billion people worldwide suffer from some form of neurological disorder, such as Alzheimer's (AD), Parkinson's (PD), multiple sclerosis, traumatic brain injury, epilepsy, stroke, or spinal injury. These conditions result in more than 7 million deaths, with associated costs exceed…

TS-075248 — Problem High-grade serous ovarian cancer (HGSOC) accounts for over 75% of all epithelial OC and has a high mortality rate due to a lack of early detection methods. Current biomarkers have low sensitivity and specificity in early-stage disease. There is an urgent need for a more effective diagnosis …

TS-075246 — Problem Peripheral neuropathy, especially small fiber neuropathy, is a debilitating condition that affects millions and is commonly linked to aging, diabetes, and metabolic disorders. Existing diagnostic tools are often invasive, expensive, or they lack the sensitivity to detect early disease stage…

TS-075244 — Problem Acute myeloid leukemia (AML), the most common acute leukemia in adults, is a clinically and molecularly heterogeneous disease. Sequencing of large patient cohorts has uncovered a complex mutational landscape in AML but still fails to completely explain the biological and clinical heterogene…

TS-075237 — Problem The loss or mutation of serine/threonine kinase 11 (STK11), observed in 20–25% of non-small cell lung cancer (NSCLC) cases, is associated with poor prognosis and resistance to immune checkpoint blockade (ICB). While STK11 alterations are commonly linked to immunotherapy resistance, so…

TS-075230 — Problem Computed tomography (CT) is commonly used for its widespread availability, rapid acquisition times, and depiction of fine bony detail, but it struggles to differentiate spinal cord tissue from cerebrospinal fluid (CSF) due to their similar mass densities. Magnetic resonance imaging (MRI) of…

TS-075182 — PROBLEM Prostate cancer (PCa) and urothelial cancers (UC) are among the most commonly diagnosed malignancies in aging adults, and their management is characterized by prolonged, costly, and invasive surveillance pathways. Both diseases exhibit marked molecular heterogeneity that drives prognosis, t…

TS-075177 — Problem Glioblastoma multiforme (GBM) is the most malignant form of gliomas and the most lethal primary brain tumors in adults. Current biomarkers or clinical features from tissue biopsy samples cannot distinguish glioma true progression from pseudoprogression and might not be suited to monitoring …

TS-075168 — Problem Metastasis is the primary driver of cancer-related deaths, yet accurately predicting its onset is a major clinical challenge. Current diagnostic tools often fail to detect occult metastatic cells and metastatic precursor cells, resulting in either overdiagnosis, with unnecessary treatments,…

TS-075158 — Problem The global immune checkpoint inhibitor (ICI) market is ~$60B. However, only ~20% of patients derive long-term survival benefit. The current standard of care biomarker Tumor Mutation Burden (TMB) performs poorly and there is no universal biomarker with robust validated predictive ability. Opportunity A companion diagnostic for identifying patients who benefit with ICI would unlock a large market by improving patient outcome and enabling a pan-cancer treatment indication that helps newer market entrants to better compete with incumbents. Solution Genomic Score that Predicts Survival: We have developed a pan-cancer genomic scoring system encompassing ~170 genes that predicts long term survival with immune checkpoint inhibition (ICI) Derivation: Developed from next-generation sequencing genomic data from 54 Neuroendocrine neoplasms who received ICIs at OSU Validation: Performed by analyzing and scoring 20,563 genomic alterations in 1,662 ICI treated patients with 10 different cancers from a publicly available dataset. (Samstein et al., Nature Genetics 2019). Broad Applicability: NSCLC, Melanoma, Colorectal Cancer, Bladder cancer and Neuroendocrine Neoplasms. Competitive Advantage The genomic score performed better than the TMB score (current standard of care) AUC of 0.87-0.95 for genomic score vs AUC of 0.57 for TMB Predictive of survival in 5 types of cancer including NSCLC Applications Biotech/Pharma companies: Develop a companion diagnostic to facilitate ICI drug development and improve patient outcome that leads to a new pan-cancer treatment indication that competes strongly with established players such as Keytruda and Opdivo which lose patent exclusivity within 3 years Payors/Nationalized Health Systems: Accurately predicting survival benefit helps maximize benefit from expenditure on ICI